Cochrane Evidence Synthesis and Methods ►

De novo mTOR inhibitor immunosuppression versus calcineurin inhibitor immunosuppression for liver transplant recipients

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To evaluate the benefits and harms of de novo mTOR inhibitor-based versus calcineurin inhibitor-based immunosuppression for liver transplant recipients.

This is a protocol.

Published:

4 August 2023

Authors:

Kollbeck S, Graß J-K, Hillingsø JG, Penninga L

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Kollbeck S, Graß J-K, Hillingsø JG, Penninga L. De novo mTOR inhibitor immunosuppression versus calcineurin inhibitor immunosuppression for liver transplant recipients (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 8. Art. No.: CD013997. DOI: 10.1002/14651858.CD013997.